ArticleResearch and practice in thrombosis and haemostasis2026
Outcomes in venous thromboembolism with retained vs removed inferior vena cava filters: an analysis from the Registro Informatizado de Enfermedad TromboEmbólica.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing inferior vena cava filter practices: lessons from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retrievable inferior vena cava (IVC) filters are used in patients with acute venous thromboembolism (VTE) who have temporary contraindications to anticoagulation. Although guidelines recommend removing filters once anticoagulation is feasible, many filters remain in place. Long-term consequences of retention remain unclear. Objectives: This study compared clinical outcomes in patients with VTE and retrievable IVC filters, according to filter status and anticoagulation use. Methods: We analyzed patients from the international RIETE (Registro Informatizado de Enfermedad TromboEmbólica) registry who received retrievable IVC filters. Outcomes from day 90 onward were stratified by filter status (removed vs retained) and anticoagulation (on vs off). Primary endpoints included VTE recurrence, major bleeding, and all-cause mortality. Filter-related complications were assessed. Results: Among 1186 patients (mean age, 62 years; 51% male), 51.9% had filters removed by day 90. Patients with retained filters more often had active cancer and received longer anticoagulation, primarily low-molecular-weight heparin. VTE recurrence was higher with retained filters (4.5-6.5 vs 1.2-1.3 events per 100 patient-years), mainly as deep vein thrombosis; removal was associated with lower risk (adjusted incidence rate ratio, 0.29; 95% CI, 0.15-0.54). All-cause mortality was higher in patients with retained filters (7.3-17.7 vs 3.8-4.5; removal: adjusted odds ratio, 0.53; 95% CI, 0.34-0.81). Major bleeding was infrequent, with higher rates in patients with retained filters off anticoagulation. Filter-related complications were rare and did not differ significantly between groups after adjustment. Conclusion: In this large registry, retained IVC filters were associated with higher risk of VTE recurrence, even with extended anticoagulation. Findings support structured follow-up and timely filter retrieval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.